Table 1 Baseline characteristics of study population stratified by AKI duration
From: Duration of acute kidney injury in critically ill patients
SAILS patients AKI n = 238 | Short duration AKI n = 76 | Medium duration AKI n = 47 | Persistent AKI n = 77 | Death during AKI n = 38 | |
|---|---|---|---|---|---|
Baseline characteristics | |||||
Age in years | 54 [40, 66] | 50 [40, 65] | 53 [39, 65] | 54 [40, 66] | 58 [47, 68] |
Female gender, n (%) | 114 (47.9) | 32 (42.1) | 23 (48.9) | 40 (51.9) | 19 (50.0) |
White race, n (%) | 181 (76.1) | 58 (76.3) | 36 (76.6) | 58 (75.3) | 29 (76.3) |
Hispanic or Latino, n (%) | 32 (13.4) | 14 (18.4) | 7 (14.9) | 8 (10.4) | 3 (7.9) |
BMI (kg/m2) | 28.6 [23.6, 34.2] | 28.0 [22.5, 33.3] | 26.4 [22.8, 32.1] | 30.5 [25.7, 34.6] | 27.9 [24.0, 34.7] |
Medical admission, n (%) | 218 (91.6) | 70 (92.1) | 41 (87.2) | 70 (90.9) | 37 (97.4) |
ICU days before study enrollment n (%) | 1 [1, 2] | 1 [1, 2] | 2 [1, 3] | 1 [1, 2] | 2 [1, 2] |
Rosuvastatin therapy, n (%) | 120 (50.4) | 33 (43.4) | 19 (40.4) | 46 (59.7) | 22 (57.9) |
Day of randomization APACHE III | 98 [81, 121] | 92 [78, 107] | 91 [73, 112] | 105 [89, 123] | 121 [95, 139] |
Comorbidities | |||||
Diabetes mellitus, n (%) | 53 (22.3) | 16 (21.1) | 10 (21.3) | 17 (22.1) | 10 (26.3) |
Hypertension, n (%) | 112 (47.1) | 35 (46.1) | 20 (42.6) | 35 (45.5) | 22 (57.9) |
Congestive heart failure, n (%) | 16 (6.7) | 2 (2.6) | 5 (10.6) | 8 (10.4) | 1 (2.6) |
Peripheral vascular disease, n (%) | 12 (5.0) | 4 (5.3) | 3 (6.4) | 4 (5.2) | 1 (2.6) |
Chronic pulmonary disease, n (%) | 35 (14.7) | 13 (17.1) | 7 (14.9) | 10 (13.0) | 5 (13.2) |
Cancer, n (%) | 38 (16.0) | 14 (18.4) | 4 (8.5) | 8 (10.4) | 12 (31.6) |
Day of AKI development | |||||
Study day that AKI developed | 1 [1, 3] | 2 [1, 3] | 1 [1, 3] | 1 [1, 2] | 1 [1, 2] |
Urine output (mL/kg/h) | 0.78 [0.28, 1.48] | 1.05 [0.70, 1.81] | 1.36 [0.58, 2.87] | 0.43 [0.06, 0.86] | 0.31 [0.12, 0.88] |
Platelets × 106/L | 168 [74, 256] | 204 [120, 292] | 185 [115, 272] | 143 [67, 220] | 68 [26, 184] |
Vasopressor use, n (%) | 105 (44.3) | 22 (28.9) | 13 (27.7) | 39 (51.3) | 31 (81.6) |
Systolic BP (mm Hg) | 90 [80, 100] | 94 [85, 105] | 92 [82, 107] | 86 [79, 98] | 78 [70, 89] |
PaO2/FiO2 ratio | 155 [110, 220] | 184 [129, 257] | 192 [133, 272] | 147 [106, 190] | 123 [87, 151] |
AKI characteristics | |||||
Baseline creatinine (mg/dL) | 1.0 [0.7, 1.4] | 0.9 [0.7, 1.4] | 0.9 [0.6, 1.3] | 1.2 [0.7, 1.9] | 1.0 [0.7, 1.2] |
Creatinine at AKI diagnosis (mg/dL) | 1.7 [1.2, 2.6] | 1.4 [1.0, 2.0] | 1.4 [1.1, 2.0] | 2.4 [1.6, 3.8] | 1.8 [1.4, 2.4] |
On dialysis, n (%) | 25 (10.5) | 1 (1.3) | 0 (0.0) | 18 (23.4) | 6 (15.8) |
KDIGO AKI stage at presentation | |||||
Stage 1, n (%) | 172 (72.3) | 72 (94.7) | 40 (85.1) | 35 (45.5) | 25 (65.8) |
Stage 2, n (%) | 25 (10.5) | 1 (1.3) | 5 (10.6) | 14 (18.2) | 5 (13.2) |
Stage 3, n (%) | 41 (17.2) | 3 (3.9) | 2 (4.3) | 28 (36.4) | 8 (21.1) |
KDIGO AKI maximum severity stage day 1–7 | |||||
Stage 1, n (%) | 116 (48.7) | 63 (82.9) | 31 (66.0) | 13 (16.9) | 9 (23.7) |
Stage 2, n (%) | 36 (15.1) | 5 (6.6) | 12 (25.5) | 11 (14.3) | 8 (21.1) |
Stage 3, n (%) | 86 (36.1) | 8 (10.5) | 4 (8.5) | 53 (68.8) | 21 (55.3) |